Erschienen in:
01.04.2008 | Case Report
Infliximab can induce a prolonged clinical remission and a decrease in thyroid hormonal requirements in a patient with SAPHO syndrome and hypothyroidism
verfasst von:
Francisca Sabugo, Claudio Liberman, Juan Pablo Niedmann, Lilian Soto, Miguel Cuchacovich
Erschienen in:
Clinical Rheumatology
|
Ausgabe 4/2008
Einloggen, um Zugang zu erhalten
Abstract
SAPHO syndrome is a rare entity that compromises the skeletal system (arthritis–osteitis) and is associated with various dermatological conditions such as palmoplantaris pustulosis (PPP) and acne. We present the case of a 39-year-old man with invalidating arthritis derived from a SAPHO syndrome and hypothyroidism (after radioiodine treatment for a Graves’ disease). Due to the severity and refractoriness of his disease, we decided to use infliximab. He showed a prompt and prolonged response of his joint and cutaneous manifestations after three doses of a tumor necrosis factor alpha (TNF-α) blocker. Interestingly, he also decreased his levothyroxine requirements after TNF-α blockade therapy.